Tanya L. Hoskin

Tanya L. Hoskin

Auto-generated profile, based on publicly available information

Tanya L. Hoskin

Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Neoplasia
Verified
Journal Article
Open access
THTina J. Hieken
Tina J. Hieken
JCJun Chen
Jun Chen
BCBeiyun Chen
Beiyun Chen
SJStephen Johnson
Stephen Johnson
THTanya L Hoskin
Tanya L Hoskin
NCNicholas Chia
Nicholas Chia
Stromal and immune cell composition alterations in benign breast tissue associate with future cancer risk. Pilot data suggest the innate microbiome of normal breast tissue differs between women with and without breast cancer. Microbiome alterations might explain tissue microenvironment variations associated with disease status. Prospectively-collected sterile normal breast tissues from women with benign (n=16) or malignant (n=17) disease underwent 16SrRNA sequencing with Illumina MiSeq and Hybrid-denovo pipeline processing. Breast tissue was scored for fibrosis and fat percentages and immune cell infiltrates (lobulitis) classified as absent/mild/moderate/severe. Alpha and beta diversity were calculated on rarefied OTU data and associations analyzed with multiple linear regression and PERMANOVA. Breast tissue stromal fat% was lower and fibrosis% higher in benign disease versus cancer (median 30% versus 60%, p=0.01, 70% versus 30%, p=0.002, respectively). The microbiome varied with stromal composition. Alpha diversity (Chao1) correlated with fat% (r=0.38, p=0.02) and fibrosis% (r=-0.32, p=0.05) and associated with different microbial populations as indicated by beta diversity metrics (weighted UniFrac, p=0.08, fat%, p=0.07, fibrosis%). Permutation testing with FDR control revealed taxa differences for fat% in Firmicutes, Bacilli, Bacillales, Staphylococcaceae and genus Staphylococcus, and fibrosis% in Firmicutes, Spirochaetes, Bacilli, Bacillales, Spirochaetales, Proteobacteria RF32, Sphingomonadales, Staphylococcaceae, and genera Clostridium, Staphylococcus, Spirochaetes, Actinobacteria Adlercreutzia. Moderate/severe lobulitis was more common in cancer (73%) than benign disease (13%), p=0.003, but no significant microbial associations were seen. These data suggest a link between breast tissue stromal alterations and its microbiome, further supporting a connection between the breast tissue microenvironment and breast cancer.

1 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GCGrace M. Choong
Grace M. Choong
THTanya L. Hoskin
Tanya L. Hoskin
JBJudy C. Boughey
Judy C. Boughey
JIJames N. Ingle
James N. Ingle
MGMatthew P. Goetz
Matthew P. Goetz
PURPOSE: Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS: Using the National Cancer Database, we studied patients with high-risk stage I to III, ER-low BC (defined as immunohistochemistry 1%-10%) who received (neo)adjuvant chemotherapy and did or did not initiate ET. OS was analyzed with ET initiation as a time-dependent covariate using Cox proportional hazards regression. RESULTS: Of 10,362 patients with stage I to III ER-low BC, 7,018 received chemotherapy and met inclusion criteria. ET omission was 42% at 12 months and more common in patients with tumors that were progesterone receptor–negative, human epidermal growth factor receptor 2–negative, higher-grade (grade 2/3) and higher Ki-67 (≥20%; all P < .001) and those who received neoadjuvant chemotherapy (NAC; P < .001). With a median follow-up of 3 years, 586 deaths were observed. In a multivariable analysis, ET omission was associated with a higher risk of death (hazard ratio [HR], 1.23 [95% CI, 1.04 to 1.46]; P = .02), with a greater impact in those with higher ER levels: ER 1%-5% (HR, 1.15 [95% CI, 0.91 to 1.45]; P = .24) versus ER 6%-10% (HR, 1.42 [95% CI, 1.00 to 2.02]; P = .048). Among patients treated with NAC (n = 4,377, 62%), ET omission was associated with worse OS in those with residual disease (RD; HR, 1.26 [95% CI, 1.00 to 1.57]; P = .046) but not in those who achieved a pathologic complete response (HR, 1.06 [95% CI, 0.62 to 1.80]; P = .84). CONCLUSION: In ER-low, early-stage BC, ET omission is associated with significantly worse OS, especially in patients with RD after NAC and those with higher (6%-10%) ER levels. Until prospective data are available, patients with ER-low BC should be counseled regarding the potential benefit of ET.

2 June 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VSVera J. Suman
Vera J. Suman
LDLili Du
Lili Du
THTanya Hoskin
Tanya Hoskin
MAMeenakshi Anurag
Meenakshi Anurag
Cynthia MaCynthia Ma
Cynthia Ma
WSW. Fraser Symmans
W. Fraser Symmans
Purpose: To evaluate prediction of response and event-free survival (EFS) following neoadjuvant endocrine therapy by SET2,3 index of nonproliferation gene expression related to estrogen and progesterone receptors adjusted for baseline prognosis. Experimental Design: A correlative study was conducted of SET2,3 measured from gene expression profiles of diagnostic tumor (Agilent microarrays) in 379 women with cStage II–III breast cancer from the American College of Surgeons Oncology Group Z1031 neoadjuvant aromatase inhibitor trial SET2,3 was dichotomized using the previously published cutoff. Fisher exact test was used to assess the association between SET2,3 and low proliferation at week 2–4 [Ki67 ≤ 10% or complete cell-cycle arrest (CCCA; Ki67 ≤ 2.7%)] and PEPI-0 rate in cohort B, and the association between SET2,3 and ypStage 0/I in all patients. Cox models were used to assess EFS with respect to SET2,3 excluding cohort B patients who switched to chemotherapy. Results: Patients with high SET2,3 had higher rate of pharmacodynamic response than patients with low SET2,3 (Ki67 ≤ 10% in 88.2% vs. 56.9%, P < 0.0001; CCCA in 50.0% vs. 26.2%, P = 0.0054), but rate of ypStage 0/I (24.0% vs. 20.4%, P = 0.4580) or PEPI = 0 (28.4% vs. 20.6%, P = 0.3419) was not different. Patients with high SET2,3 had longer EFS than patients with low SET2,3 (HR, 0.52, 95% confidence interval: 0.34–0.80; P = 0.0026). Conclusions: This exploratory analysis of Z1031 data demonstrated a higher rate of pharmacodynamic suppression of proliferation and longer EFS in high SET2,3 disease relative to low SET2,3 disease. The ypStage 0/I rate and PEPI = 0 rate were similar with respect to SET2,3.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RKR. Katipamula
R. Katipamula
THT. L. Hoskin
T. L. Hoskin
JBJ. C. Boughey
J. C. Boughey
ADA. C. Degnim
A. C. Degnim
CGC. S. Grant
C. S. Grant
MGM. P. Goetz
M. P. Goetz
509 Background: Surgical treatment for early stage breast cancer (ca) includes mastectomy (mast) or lumpectomy. The influence of preoperative breast magnetic resonance imaging (pMRI) on mast rates is unknown. We sought to analyze trends in mast rates and their relationship to breast MRI and surgical year (yr) at the Mayo Clinic Rochester. Methods: A cohort of 5,596 stage 0–2 breast cas in 5,463 pts who had surgery between 1997–2006 were identified retrospectively. Surgery type was defined using institutional surgical index and tumor registry. All pts in the cohort with pMRI were identified from a prospective breast MRI database initiated in 2003. Trends over time in mast rate and the association of pMRI with surgery type were assessed. Multiple logistic regression was used to assess the effect of surgery yr and pMRI on surgery type, while adjusting for potential confounding variables. Results: TNM stage of the 5,596 breast cas was: 0- 18%, I- 48%, and II- 34%; mean age was 61 (23 to 95) yrs. Mast rates differed significantly across time (p<0.0001), and decreased from 45% in 1997 to 30% in 2003, followed by increasing rates for 2004–2006 (Table 1). Pts with pMRI were more likely to undergo mast than those without pMRI (52% vs 38%, p<0.0001); however a similar increase in mast rates was seen among pts without pMRI (28% in 2003 to 41% in 2006; p<0.0001). In a multivariate model adjusted for age, stage, contralateral breast ca, and density, both MRI (Odds Ratio (OR): 1.7, p<0.0001) and surgical yr (compared to 2003; OR: 1.4 for 2004, 1.9 for 2005, and 1.7 for 2006; p<0.0001) were independent predictors of mast. Conclusions: Following a steady decline over 7 years, mast rates have increased in recent years and are similar to 1997, with both surgery yr and pMRI as significant predictors of type of surgery. Because type of local therapy may not influence survival, further studies are needed to evaluate the role of pMRI and other factors influencing preoperative surgical planning. No significant financial relationships to disclose.

18 October 2023 in Surgery
Verified
Journal Article
Closed access
JSJessica A. Steadman
Jessica A. Steadman
THTanya L. Hoskin
Tanya L. Hoskin
CKChristine Klassen
Christine Klassen
JBJudy C. Boughey
Judy C. Boughey
ADAmy C. Degnim
Amy C. Degnim
THTina J. Hieken
Tina J. Hieken

24 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ADAmy C. Degnim
Amy C. Degnim
BSBrittany Siontis
Brittany Siontis
SASafia K Ahmed
Safia K Ahmed
THTanya L. Hoskin
Tanya L. Hoskin
THTina J. Hieken
Tina J. Hieken
IPIvy A. Petersen
Ivy A. Petersen
Purpose: To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. Experimental Design: With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins. Results: A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing. Conclusions: Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.